US Stock Surge: Grail Soars on September 30 as FDA Supports Multi-Cancer Early Screening

Grail September 30th Surge Interpretation

Keywords: FDA support, multi-cancer early screening

1. On September 23rd, the FDA Molecular and Clinical Genetics Devices Panel reviewed the Galleri premarket approval application. Safety was unanimously approved with 10:0 votes; benefit over risk was approved with a 7:2 vote; efficacy was approved with a 6:4 vote, providing regulatory progress for the subsequent PMA approval process.

2. On September 21st, the FDA review file did not identify any major issues regarding the accuracy or safety of Galleri. The company had submitted the PMA application on January 29th, and the regulatory review process is ongoing.

3. As of June 30th, GRAIL’s main business is early multi-cancer detection. The commercialized Galleri blood test can screen for multiple cancers and predict the origin of cancer signals. The company disclosed a total of $861.6 million in cash and short-term marketable securities, which can meet operational and capital expenditure needs for at least the next 12 months.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)